## **International Cancer Research Partnership (ICRP) Annual Report FINAL** - **Charity name:** International Cancer Research Partnership - **Charity registration number:** 1204566 - **Report covering the period:** 1 April 2024 – 31 March 2025 ## **Objectives and Activities** ## **Summary of the purposes of the charity as set out in its governing document[1]** To promote and protect the good health of people affected by cancer and the public by promoting collaboration between cancer research funders across the world and by coordinating research into the causes, prevention, treatment and cure of all forms of cancer, to maximise the value and benefits of cancer research. **Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts[2]** 1. Provision of a public database of global cancer research projects - classified by research and cancer type - that are funded by the partner organisations, to enable cancer researchers and funders to identify opportunities for collaboration, avoid duplication, and highlight gap areas where further investment is required to enhance research for the benefit of cancer patients and the public. 2. Enhancing communication between cancer research funders to promote collaboration, share knowledge and maximise resources by avoiding duplicative activities. This is achieved through monthly online meetings for partners, an annual meeting, and provision of resources through the partner website and forum. 3. Publish regular reports on global cancer research activity, to highlight opportunities to enhance research, for the benefit of partners, patients, policymakers and the wider public. **Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit[3]** The trustees have complied with their duty to have due regard to the commission's public benefit guidance ## **Achievements and Performance** **Summary of the main achievements of the charity, identifying the difference the charity’s work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole[4]** > _1 SORP reference Para 1.17 2 SORP reference Para 1.17 and 1.19 3 SORP reference Para 1.18_ > _4 SORP reference Para 1.20_ ## 1. **Enhancing the database of cancer research** In 2024-25, 54,438 new projects were uploaded to the database (an increase from 7701 in 2023-24) and updates processed for 306 projects. Essential maintenance was conducted for the website and database, and further enhancements were also made to the database search on the website to improve the user experience. ## 2. **Co-funding between partners** To address identified gaps in cancer research, many of ICRP’s members cofunded projects with other funders. Examples included CRUK & NCI (US); AECC (Spain) & WCR (Scotland); AECC (Spain), CRUK, AIRC (Italy); MRA (US) & RTFCCR (Switzerland). ## 3. **Publications, evaluations and analysis** - a. **Metastatic Breast Cancer:** an ICRP sub-group continued working with the Metastatic Breast Cancer Alliance (MBCA), to analyse investment in metastatic breast cancer (MBC) research from 2014-2020. The report had already identified that previously (2000-2013), 7% of the $15 billion in breast cancer research dollars globally was for MBC. In 2014-2020, 13% of all breast cancer research dollars was devoted to MBC and investment in treatment resistance had increased (see summary). Patient advocates identified five new priority areas to examine (research into: Survivorship, Pregnancy, Microenvironment, Brain & leptomeningeal disease, Treatment - rare sub-types) with the aim of producing a report for the MBCA partners’ meeting in Spring 2026. - b. **ICRP reports:** essential preparatory work was done to underpin future analyses on childhood cancer, survivorship and global landscape analyses. - c. **Gender & PI:** an international sub-group of partner representatives in support of the Lancet Commission on Women, power and cancer analysed the gender of principal investigators in ICRP projects, in preparation for a publication later in 2025/early 2026. ## 4. **Membership and communications** Newsletters were published via the website and distributed by email to potential new partners. Funding opportunities from partner organisations were highlighted on the ICRP website and by Twitter/X to attract global applicants. Discussions were ongoing with the European Commission on including funded projects that had been coded to research and cancer type as part of the Lancet Commission roadmap for cancer research in Europe in 2022 in the ICRP database. New potential partners were identified during the course of the year. ## 5. **Patient engagement** Patient advocates led the identification of priority questions in the Metastatic Breast Cancer Analysis, and presented a panel at the May 2024 partner meeting. ## 6. **Annual and virtual meetings** A hybrid in-person/remote partner meeting was held in Toronto in May 2024, on the theme “Doing More Together”. Over 130 participants attended from 12 countries. Open sessions held on May 14[th] and 15[th] focused on Global Oncology - Challenging the Status Quo through Collaboration, Cancer Clinical Trials, AI in Cancer Research, Innovative cancer research funding models, Research Impact, - Patient Engagement and Identifying and Funding Game Changing Research. The meeting report was published in June 2024 and a list of priority areas was produced to follow up during the year. Five virtual partner meetings were held with presentations from partners on topics of interest or collaborative funding opportunities. ## 7. **Organisation, finance & operations** The process of migrating financial functions to a UK bank continued and the Charities Aid Foundation Bank (CAF Bank) was identified as the preferred option [Post AGM Note: Completed in August 2025] ## **Financial Review** |**Financial Review**||| |---|---|---| |Review of the charity’s financial position at the end of
theperiod|Para
1.21|See Fiscal Statement
(Appendix)| |Statement explaining the policy for holding reserves
stating why they are held|Para
1.22|6 month operational
reserve for winding up
operations| |Amount of reserves held|Para
1.22|£80K ($100K USD)| |Reasons for holding zero reserves|Para
1.22|n/a| |Details of fund materially in deficit|Para
1.24|n/a| |Explanation of any uncertainties about the charity
continuing as a going concern|Para
1.23|n/a| ## **Additional information (optional)** The charity’s principal sources of funds (including any Membership dues fundraising) SORP Para 1.47 ## **Structure, Governance and Management** ## **Description of charity’s trusts:** |**Description of charity’s trusts:**|**Description of charity’s trusts:**|**Description of charity’s trusts:**|**Description of charity’s trusts:**| |---|---|---|---| ||Type of governing document|Para
1.25|Association Model Constitution| ||How is the charity constituted?|Para
1.25|Charitable Incorporated
Organisation| ||Trustee selection methods including
details of any constitutional provisions e.g.
election to post or name of any person or
body entitled to appoint one or more
trustees|Para
1.25|Skills audit| ## **Reference and Administrative details** |Charity name|International Cancer Research Partnership| |---|---| |Other name the charity
uses|n/a| |Registered charity
number|1204566| |Charity’s principal
address|International House, 10 Churchill Way, Cardiff, CF10 2HE, UK| ## **Names of the charity trustees who manage the charity** |**Trustee Name**|**Ofice (if**
**any)**|**Dates acted if not**
**for whole year**|**Dates acted if not**
**for whole year**|**Name of person (or body)**
**entitled to appoint trustee**
**(if any)**| |---|---|---|---|---| |Iain Frame||Resigned Sep2024||| |KimberlyBadovinac||||| |Katherine McKenzie||||| |Lynn Turner||||| |Richard Stephens||||| |Sarah McDonald||||| |**Declarations**
The trustees declare that they have approved the trustees’ report above.
Signed on behalf of the charity’s trustees
Signature(s)
Full name(s)
Lynn Turner
Sarah McDonald
Position (e.g.
Trustee, Secretary,
Chair etc.)
Trustee
Trustee
Date
23/01/26
23/01/2026||||| |Signature(s)||||| |Full name(s)|||Sarah McDonald|| |Position (e.g.
Trustee, Secretary,
Chair etc.)|||Trustee|| |Date|||23/01/2026|| Appendix Intornational Cancer Research Partners IICRPI FINANCIAL REPORT for th• period of April 1, 2024 - Mar¢h 31, 2025 Chaii. Finance Committee Kiniberty Ba(k>vinac Host In81iwiSon Canadian Partnershi 5(KIRCESOF FUNDS BaL￿n￿ of futKts as of 11,2024 m￿t￿p Fees for FY23f24 receNed in FY24f25 (Note 21 Merrbersh" for FY24f25 Toial fiiiids available for A ril 1, 2024 March 31, 2025 EXp￿1[￿jRES WIC11114ED Spon50r Asat ICRP March 31. 2Q25 ainst Cancer USD 202,459 8.rifrJ 00 25.000 00 235 459.90 11 SaLary and Benefits Fee 45.098 53 Subtotol al ICRP webex& othw SU￿C￿p￿ etc. bl Travel & Èynses 2.364 21 12.745 10 Subtotal 15.109.31 60.207.84 1T5.252. 175,252. 186.219.89 87 032.17 Totcil ex iiclitiires incurted ril 1, 2024. March 31, 2025 UNSPEMt BALANCE TOTAL BALANCE USD UnrÈalizÈd forelyn Èxthange losses INotÈ 11 Total Ad usted Balenee USD SIGNATURE Note 1.. &is at Maich 31. 2025, the USD eqUiva￿￿t of ￿ $125,118.13 CAD balance in CPAC'S •¢c¢)unt is $87,032.17 USD using an exchangE rate of 0.6956. This difference is due to the effect of accumulated cwtency fluctuation sintÈ August 1. 2013, the unreolized foreign exch6nge108ses are 588,219.89 USD. Noie 2.. FY23124 membership feeol USD frcffiJapon P4ency lor Medical R￿¥¢h c￿￿O￿￿t￿a$ receivedon W"1 ab24￿d reffected in Ff24Q5 State￿￿t ek¥*TrYrfure5 1fKU￿e4 Ixhafcl ttEgrdrtt￿. trHlthe ￿(￿U￿￿ a¥all*fu nKfftiIc￿rQ pJyc6e5. Jessie Yin. CPA.CGA CthtrVl￿r. Finan￿ & AdnNrYsltat C4n•Jian Partnership 4*nsl Cancer May 9, 2025